Amubarvimab
drugOn this page
Also known as Brii 196Brii-196BRII196
Summary
Amubarvimab (CHEMBL4650382) is a phase-3 clinical-stage antibody; indicated across 1 condition including severe acute respiratory syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 1 condition
- Clinical trials: 7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650382 |
| Name | Amubarvimab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Amubarvimab, Brii 196, Brii-196, BRII-196, BRII196, AMUBARVIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
Clinical trials
Total trials: 7.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04501978 | PHASE3 | COMPLETED | ACTIV-3: Therapeutics for Inpatients With COVID-19 |
| NCT04518410 | PHASE2/PHASE3 | COMPLETED | ACTIV-2: A Study for Outpatients With COVID-19 |
| NCT05780424 | PHASE3 | COMPLETED | BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| NCT04770467 | PHASE2 | WITHDRAWN | A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19 |
| NCT04787211 | PHASE2 | COMPLETED | A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 |
| NCT04479631 | PHASE1 | COMPLETED | Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196 |
| NCT04691180 | PHASE1 | COMPLETED | A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: severe acute respiratory syndrome